|
|
|
|
|
|
|
|
Abstract
"Aspirin or acetylsalicylic acid (ASA) is commonly used in the
general population for primary prevention of cardiovascular disease
(CVD). Strong evidence supports the use of ASA in secondary prevention
of CVD; however, for primary prevention, potential benefits are offset
by potential harms (primarily major bleeds), with no benefit in overall
mortality. Anti-platelet agents, including ASA, are one of the most
commonly implicated medications for hospital admissions related to
adverse medication events. Studies of primary prevention in patients
with risk factors for CVD also fail to show a benefit with ASA. Finally,
evidence supporting ASA use for cancer prevention is limited. Health
care providers should be aware of the benefits and risks associated with
ASA use in primary and secondary prevention and discuss these with
their patients in the context of individual patient values and
preferences."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.